Download PDF
CC BY-NC-ND 4.0 · Indian Journal of Neurosurgery 2021; 10(03): 230-235
DOI: 10.1055/s-0041-1726610
Original Article

Serum Progesterone Levels as Predictor of Outcome in Severe Traumatic Brain Injury: Analysis of Cohort of 100 Patients

Sarbjit Singh Chhiber
1   Department of Neurosurgery, Sher-e-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
,
Adfer Gul
2   Department of Plastic Surgery, Sher-e-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
,
Sajad Arif
1   Department of Neurosurgery, Sher-e-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
,
Abrar Ahad Wani
1   Department of Neurosurgery, Sher-e-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
,
Altaf Umar Ramzan
1   Department of Neurosurgery, Sher-e-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Despite advances in research and improved neurological intensive care in recent years, the clinical outcome of severely head injured patients is still poor. Primary insult is followed by a complex cascade of molecular and biochemical events that lead to neuroinflammation, brain edema, and delayed neuronal death. No specific pharmacological therapy is currently available which prevents the development of secondary brain injuries, and most therapeutic strategies have failed in translation from bench to bedside. There are limitations of clinical and radiological methods in delineating the exact severity and prognosis of traumatic brain injury (TBI). A myriad complex biochemical markers are under investigation to delineate the extent of brain tissue damage and to independently predict the outcome, but a search for simple biomarker still eludes the research. Progesterone, a gonadal hormone and a neurosteroid, although controversial as a neuroprotective agent, may hold promise as a simple biochemical marker of the outcome in severe TBI.

Keywords

severe traumatic brain injury - progesterone - biochemical marker - outcome


Publication History

Article published online:
25 March 2021

© 2021. Neurological Surgeons’ Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Roberts I, Schierhout G, Alderson P. Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: a systematic review. J Neurol Neurosurg Psychiatry 1998; 65 (05) 729-733
    CrossrefPubMedGoogle Scholar
  • 2 Wrona RM. The use of state workers’ compensation administrative data to identify injury scenarios and quantify costs of work-related traumatic brain injuries. J Safety Res 2006; 37 (01) 75-81
    CrossrefPubMedGoogle Scholar
  • 3 Davis KL, Joshi AV, Tortella BJ, Candrilli SD. The direct economic burden of blunt and penetrating trauma in a managed care population. J Trauma 2007; 62 (03) 622-629
    CrossrefPubMedGoogle Scholar
  • 4 Gamboa Jr AMJ, Holland GH, Tierney JP, Gibson DS. American Community Survey: earnings and employment for persons with traumatic brain injury. NeuroRehabilitation 2006; 21 (04) 327-333
    CrossrefPubMedGoogle Scholar
  • 5 Woolhandler S, Himmelstein DU. Double catastrophe: injury-related bankruptcies. Med Care 2007; 45 (08) 699-701
    CrossrefPubMedGoogle Scholar
  • 6 Stahel PF, Smith WR, Moore EE. Hypoxia and hypotension, the “lethal duo” in traumatic brain injury: implications for prehospital care. Intensive Care Med 2008; 34 (03) 402-404
    CrossrefPubMedGoogle Scholar
  • 7 The Brain Trauma Foundation. Guidelines for the management of severe traumatic brain injury. J Neurotrauma 2007; 24: S1-S106
    CrossrefPubMedGoogle Scholar
  • 8 Beauchamp K, Mutlak H, Smith WR, Shohami E, Stahel PF. Pharmacology of traumatic brain injury: where is the “golden bullet”?. Mol Med 2008; 14 (11-12) 731-740
    CrossrefPubMedGoogle Scholar
  • 9 Howard RB, Sayeed I, Stein DG. Suboptimal dosing parameters as possible factors in the negative phase III clinical trials of progesterone for traumatic brain injury. J Neurotrauma 2017; 34 (11) 1915-1918
    CrossrefPubMedGoogle Scholar
  • 10 Roof RL, Hoffman SW, Stein DG. Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol Chem Neuropathol 1997; 31 (01) 1-11
    CrossrefPubMedGoogle Scholar
  • 11 Pettus EH, Wright DW, Stein DG, Hoffman SW. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Res 2005; 1049 (01) 112-119
    CrossrefPubMedGoogle Scholar
  • 12 Shear DA, Galani R, Hoffman SW, Stein DG. Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol 2002; 178 (01) 59-67
    CrossrefPubMedGoogle Scholar
  • 13 Thomas AJ, Nockels RP, Pan HQ, Shaffrey CI, Chopp M. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine 1999; 24 (20) 2134-2138
    CrossrefPubMedGoogle Scholar
  • 14 Wright DW, Bauer ME, Hoffman SW, Stein DG. Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. J Neurotrauma 2001; 18 (09) 901-909
    CrossrefPubMedGoogle Scholar
  • 15 Wright DW, Yeatts SD, Silbergleit R. et al NETT Investigators. Very early administration of progesterone for acute traumatic brain injury. N Engl J Med 2014; 371 (26) 2457-2466
    CrossrefPubMedGoogle Scholar
  • 16 Skolnick BE, Maas AI, Narayan RK. et al SYNAPSE Trial Investigators. A clinical trial of progesterone for severe traumatic brain injury. N Engl J Med 2014; 371 (26) 2467-2476
    CrossrefPubMedGoogle Scholar
  • 17 Wright DW, Kellermann AL, Hertzberg VS. et al ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007; 49 (04) 391-402
    CrossrefPubMedGoogle Scholar
  • 18 Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 2008; 12 (02) R61
    CrossrefPubMedGoogle Scholar
  • 19 Raheja A, Sinha S, Samson N. et al Serum biomarkers as predictors of long-term outcome in severe traumatic brain injury: analysis from a randomized placebo-controlled Phase II clinical trial. J Neurosurg 2016; 125 (03) 631-641
    CrossrefPubMedGoogle Scholar
  • 20 Dasgupta A, Sarma D, Saika UK. Serum progesterone as an admission prognostic marker in male traumatic brain injury patients. J Neurol Res 2012; 2 (02) 44-47
    PubMedGoogle Scholar
  • 21 Czeiter E, Mondello S, Kovacs N. et al Brain injury biomarkers may improve the predictive power of the IMPACT outcome calculator. J Neurotrauma 2012; 29 (09) 1770-1778
    CrossrefPubMedGoogle Scholar
  • 22 Wagner AK, McCullough EH, Niyonkuru C. et al Acute serum hormone levels: characterization and prognosis after severe traumatic brain injury. J Neurotrauma 2011; 28 (06) 871-888
    CrossrefPubMedGoogle Scholar
  • 23 Woodcock T, Morganti-Kossmann MC. The role of markers of inflammation in traumatic brain injury. Front Neurol 2013; 4: 18
    CrossrefPubMedGoogle Scholar
  • 24 Wei J, Xiao GM. The neuroprotective effects of progesterone on traumatic brain injury: current status and future prospects. Acta Pharmacol Sin 2013; 34 (12) 1485-1490
    CrossrefPubMedGoogle Scholar
  • 25 Dhandapani SS, Manju D, Vivekanandhan S, Agarwal M, Mahapatra AK. Prospective longitudinal study of biochemical changes in critically ill patients with severe traumatic brain injury:Factors associated and outcome at 6 months. J Neurotrauma 2010; 7: 23-27
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Takahashi H, Urano T, Takada Y, Nagai N, Takada A. Fibrinolytic parameters as an admission prognostic marker of head injury in patients who talk and deteriorate. J Neurosurg 1997; 86 (05) 768-772
    CrossrefPubMedGoogle Scholar
  • 27 Vos PE, Jacobs B, Andriessen TM. et al GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 2010; 75 (20) 1786-1793
    CrossrefPubMedGoogle Scholar
  • 28 Diaz-Arrastia R, Wang KK, Papa L. et al TRACK-TBI Investigators. Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma 2014; 31 (01) 19-25
    CrossrefPubMedGoogle Scholar
  • 29 Guzel A, Er U, Tatli M. et al Serum neuron-specific enolase as a predictor of short-term outcome and its correlation with Glasgow Coma Scale in traumatic brain injury. Neurosurg Rev 2008; 31 (04) 439-444
    CrossrefPubMedGoogle Scholar
  • 30 Chiaretti A, Antonelli A, Mastrangelo A. et al Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J Neurotrauma 2008; 25 (03) 225-234
    CrossrefPubMedGoogle Scholar
  • 31 Ferreira LC, Regner A, Miotto KD. et al Increased levels of interleukin-6, -8 and -10 are associated with fatal outcome following severe traumatic brain injury. Brain Inj 2014; 28 (10) 1311-1316
    CrossrefPubMedGoogle Scholar
  • 32 Lenzlinger PM, Morganti-Kossmann MC, Laurer HL, McIntosh TK. The duality of the inflammatory response to traumatic brain injury. Mol Neurobiol 2001; 24 (1-3) 169-181
    CrossrefPubMedGoogle Scholar
  • 33 Hall ED, Yonkers PA, McCall JM, Braughler JM. Effects of the 21-aminosteroid U74006F on experimental head injury in mice. J Neurosurg 1988; 68 (03) 456-461
    CrossrefPubMedGoogle Scholar
  • 34 Braughler JM, Pregenzer JF. The 21-aminosteroid inhibitors of lipid peroxidation: reactions with lipid peroxyl and phenoxy radicals. Free Radic Biol Med 1989; 7 (02) 125-130
    CrossrefPubMedGoogle Scholar
  • 35 Clark WM, Hazel JS, Coull BM. Lazaroids. CNS pharmacology and current research. Drugs 1995; 50 (06) 971-983
    CrossrefPubMedGoogle Scholar
  • 36 Hall ED, Braughler JM. Central nervous system trauma and stroke. II. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic Biol Med 1989; 6 (03) 303-313
    CrossrefPubMedGoogle Scholar
  • 37 Ma J, Huang S, Qin S, You C. Progesterone for acute traumatic brain injury. Cochrane Database Syst Rev 2012; 10: CD008409
    PubMedGoogle Scholar